INCY
Strong BuyFull HouseAI neutralIncyte Corporation · Healthcare · United States · $25.3B cap · $180.1M/day traded
$111.36 -1.3% · close 12 Oct · scored 14 Oct
StockRank down 1.0 since 13 Oct.
Full House: Strong business, sensible price, market agrees. The rare full house.
Report expected 27 Oct: the next-year EPS estimate has fallen 5.4% over the last 13 weeks.
As of 14 Oct 2026, MoatMap's StockRank for Incyte Corporation (INCY) is 93/100, ranked against 24,000+ stocks in 35 markets (Quality 88, Value 53, Momentum 56, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
While quantitative metrics remain strong, the 0.06% insider selling activity triggers the rule requiring neutral status despite the upward EPS revision. Insufficient evidence exists to overcome the internal signal bar for an immediate APPROVE.
ABOUT INCYTE CORPORATION
Read
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, primarily in oncology and inflammation/autoimmunity. The company possesses a robust pipeline of innovative small-molecule drugs and a flagship product, Jakafi, which holds a leading market position in myelofibrosis and polycythemia vera. It is a leading biopharmaceutical innovator, recognized for its contributions to oncology and inflammatory disease treatments.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.4B | 3.7B | 4.2B | 5.1B | 14.8% | 5.8B | 5.9B | 6.3B | 10.3% |
| EPS | 1.53 | 2.67 | 0.16 | 6.59 | 62.7% | 7.85 | 3.37 | 8.78 | 15.4% |
| Shares | 222.7M | 224.3M | 193.4M | 198.5M | -10.9% | 202.7M | — | — | — |
| Debt | 41.5M | 38.3M | 43.5M | 40.4M | -0.8% | 38.3M | — | — | — |
| Equity | 4.4B | 5.2B | 3.4B | 5.2B | 5.7% | — | — | — | — |
| Op CF | 969.9M | 496.5M | 335.3M | 1.4B | 13.4% | 2.0B | — | — | — |
| Inv CF | -78.5M | -207.7M | 157.5M | -102.6M | — | — | — | — | — |
| Fin CF | -0.8M | -20.0M | -2.0B | 101.0M | — | — | — | — | — |
Above its 200-day average and 16% below its 52-week high.
Calmer than 65% of stocks we rank over the past year (33% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INCY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INCY | Incyte Corporation(you) | $25.3B | 93 | Strong Buy |
| HALO | Halozyme Therapeutics, Inc. | $12.8B | 95 | Strong Buy |
| EXEL | Exelixis, Inc. | $14.1B | 98 | Strong Buy |
| RGO.DE | Regeneron Pharmaceuticals, Inc. | $76.9B | 89 | Strong Buy |
| CORT | Corcept Therapeutics Incorporated | $12.2B | 75 | Buy |
| TECH | Bio-Techne Corporation | $11.4B | 73 | Buy |
| VX1.DE | Vertex Pharmaceuticals Incorporated | $128.8B | 88 | Strong Buy |
| KRYS | Krystal Biotech, Inc. | $10.1B | 70 | Buy |
| BMRN | BioMarin Pharmaceutical Inc. | $12.0B | 65 | Buy |
| RPRX | Royalty Pharma plc | $33.3B | 55 | Hold |
Peer medians: ROE -26.1% · P/E 29.0x · Gross margin 64.4%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.